Stephens Investment Management Group’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,371,561
| Closed | -$39.2M | – | 165 |
|
|
2024
Q2 | $39.2M | Sell |
1,371,561
-55,184
| -4% | -$1.57M | 0.55% | 82 |
|
|
2024
Q1 | $41.7M | Buy |
1,426,745
+108,740
| +8% | +$3.34M | 0.55% | 83 |
|
|
2023
Q4 | $44.5M | Sell |
1,318,005
-25,659
| -2% | -$751K | 0.65% | 75 |
|
|
2023
Q3 | $41.2M | Buy |
1,343,664
+6,632
| +0.5% | +$239K | 0.68% | 71 |
|
|
2023
Q2 | $53.6M | Buy |
1,337,032
+164,974
| +14% | +$6.82M | 0.84% | 53 |
|
|
2023
Q1 | $47.8M | Buy |
1,172,058
+3,589
| +0.3% | +$143K | 0.8% | 56 |
|
|
2022
Q4 | $45.5M | Sell |
1,168,469
-1,059
| -0.1% | -$51.5K | 0.83% | 54 |
|
|
2022
Q3 | $62.2M | Buy |
1,169,528
+1,449
| +0.1% | +$80.6K | 1.18% | 17 |
|
|
2022
Q2 | $68.1M | Buy |
1,168,079
+7,864
| +0.7% | +$515K | 1.26% | 10 |
|
|
2022
Q1 | $88.5M | Buy |
1,160,215
+21,405
| +2% | +$1.43M | 1.3% | 10 |
|
|
2021
Q4 | $68.5M | Buy |
1,138,810
+163,928
| +17% | +$9.04M | 0.89% | 40 |
|
|
2021
Q3 | $54.6M | Buy |
974,882
+17,547
| +2% | +$1.01M | 0.74% | 56 |
|
|
2021
Q2 | $58.1M | Sell |
957,335
-14,725
| -2% | -$932K | 0.8% | 49 |
|
|
2021
Q1 | $68.1M | Buy |
972,060
+3,491
| +0.4% | +$249K | 0.99% | 31 |
|
|
2020
Q4 | $58M | Sell |
968,569
-29,769
| -3% | -$1.74M | 0.86% | 48 |
|
|
2020
Q3 | $60M | Sell |
998,338
-28,774
| -3% | -$1.67M | 1.06% | 31 |
|
|
2020
Q2 | $53.9M | Sell |
1,027,112
-214,077
| -17% | -$8.95M | 0.98% | 38 |
|
|
2020
Q1 | $41.6M | Sell |
1,241,189
-18,470
| -1% | -$767K | 1.01% | 37 |
|
|
2019
Q4 | $57.1M | Sell |
1,259,659
-3,902
| -0.3% | -$166K | 1.07% | 31 |
|
|
2019
Q3 | $48.1M | Buy |
1,263,561
+52,956
| +4% | +$2.11M | 0.96% | 40 |
|
|
2019
Q2 | $52.6M | Buy |
1,210,605
+10,868
| +0.9% | +$461K | 1% | 31 |
|
|
2019
Q1 | $45.7M | Buy |
1,199,737
+975
| +0.1% | +$38.1K | 0.93% | 41 |
|
|
2018
Q4 | $51.6M | Sell |
1,198,762
-29,727
| -2% | -$1.39M | 1.22% | 18 |
|
|
2018
Q3 | $60.4M | Buy |
1,228,489
+30,218
| +3% | +$1.31M | 1.11% | 25 |
|
|
2018
Q2 | $37.2M | Buy |
1,198,271
+146,319
| +14% | +$5.05M | 0.75% | 57 |
|
|
2018
Q1 | $32.8M | Buy |
1,051,952
+35,586
| +4% | +$1.27M | 0.71% | 62 |
|
|
2017
Q4 | $46.4M | Buy |
1,016,366
+9,266
| +0.9% | +$367K | 1.06% | 26 |
|
|
2017
Q3 | $37.8M | Buy |
1,007,100
+64,131
| +7% | +$2.58M | 0.87% | 43 |
|
|
2017
Q2 | $45M | Buy |
942,969
+45,514
| +5% | +$2.11M | 1.08% | 27 |
|
|
2017
Q1 | $40.9M | Buy |
897,455
+146,231
| +19% | +$6.32M | 1.01% | 30 |
|
|
2016
Q4 | $24.3M | Buy |
751,224
+132,719
| +21% | +$4.43M | 0.68% | 62 |
|
|
2016
Q3 | $21.2M | Buy |
618,505
+39,295
| +7% | +$1.54M | 0.63% | 73 |
|
|
2016
Q2 | $19.5M | Sell |
579,210
-1,959
| -0.3% | -$96.3K | 0.64% | 61 |
|
|
2016
Q1 | $30.8M | Buy |
581,169
+40,482
| +7% | +$2.37M | 1.08% | 23 |
|
|
2015
Q4 | $41.5M | Buy |
540,687
+49,018
| +10% | +$2.78M | 1.47% | 9 |
|
|
2015
Q3 | $20.2M | Buy |
491,669
+74,092
| +18% | +$4.54M | 0.71% | 53 |
|
|
2015
Q2 | $29.5M | Buy |
417,577
+6,810
| +2% | +$536K | 0.87% | 46 |
|
|
2015
Q1 | $36.5M | Sell |
410,767
-31,027
| -7% | -$3.15M | 1.09% | 24 |
|
|
2014
Q4 | $39.2M | Sell |
441,794
-4,370
| -1% | -$413K | 1.17% | 21 |
|
|
2014
Q3 | $43.2M | Buy |
446,164
+30,592
| +7% | +$2.98M | 1.3% | 16 |
|
|
2014
Q2 | $38.2M | Sell |
415,572
-82,850
| -17% | -$6.31M | 1.17% | 17 |
|
|
2014
Q1 | $34.9M | Sell |
498,422
-8,175
| -2% | -$556K | 1.06% | 26 |
|
|
2013
Q4 | $29.1M | Sell |
506,597
-130,590
| -20% | -$6.87M | 0.98% | 35 |
|
|
2013
Q3 | $30.6M | Buy |
637,187
+176,490
| +38% | +$6.43M | 1.06% | 30 |
|
|
2013
Q2 | $13.4M | Buy |
+460,697
| New | +$13.3M | 0.8% | 54 |
|
Other funds holding PCRX
DPCM
Stephens Investment Management Group's PCRX Position: Q3 2024 in Review
Stephens Investment Management Group sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 1,371,561 shares — an estimated $39.2M sold.
Stephens Investment Management Group first reported a position in PCRX in Q2 2013 and held it in 45 quarters. The position peaked at $88.5M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.
- Stephens Investment Management Group reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
- Stephens Investment Management Group sold 1,371,561 Pacira BioSciences shares in Q3 2024, an estimated $39.2M.
- Stephens Investment Management Group first reported a position in Pacira BioSciences in Q2 2013 and held it in 45 quarters.
- Stephens Investment Management Group's Pacira BioSciences position peaked at $88.5M in Q1 2022.
- 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.
Based on Stephens Investment Management Group's 13F filing for Q3 2024, filed 28 Oct 2024.